+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Organ-based/Targeted Drug Delivery Devices Market for Biologics (Intra-organ / Intra-tumoral), 2020 - 2030

  • PDF Icon

    Report

  • 283 Pages
  • July 2020
  • Region: Global
  • Roots Analysis
  • ID: 5141829
Description Jump to:

Overview

Over the years, advances in cell biology and pharmacology have led to the development of a variety of advanced biologics, which experts believe, possess the potential to address several unmet needs associated with the treatment of different types of diseases. Currently, there are more than 1,000 cell and gene therapies under development; most of which are being developed for the treatment of oncological disorders, cardiovascular disorders and neurological disorders. Additionally, over the last decade, multiple immunotherapies have been developed, and have led to a decrease in lung cancer and melanoma-related mortality. Despite their many benefits, biologics present a number of challenges, such as drug delivery related complexities, and immunogenicity concerns, which have been shown to result in systemic toxicity post therapy administration. To avoid such systemic toxic effects, a limited volume of drug is administered, which often results in a small amount of drug reaching the target organ. Further, from a pharmacological point of view, the drug stays at the target site for a limited time, hence decreasing the final therapeutic effect that can be achieved through prolonged and controlled drug delivery. Moreover, some of such treatment options, such as cell therapies, require periodic administration of additional therapy material, or complementary products, thereby, adding to the already complex invasive dosing procedure.   

In order to address some of the abovementioned challenges, a number of innovator companies in the biopharmaceutical sector are actively engaged in identifying targeted and effective delivery strategies for biologics, including gene therapies, cell/stem cell therapies, immunotherapies and therapeutic proteins. Examples of devices designed for the targeted delivery of biologics include (in alphabetic order, no selection criteria) Advance® CS, ExtroducerTM microcatheter, HelixTM biotherapeutic delivery system, ImmunoPulse® IL-12, SmartFlow® neuro ventricular cannula and MailPan®. Some of the aforementioned drug delivery devices have been demonstrated to have an improved therapeutic safety index, and are capable of accurately delivering biological interventions to the target physiological site. Further, certain implantable delivery systems have also been developed in order to prolong the therapeutic effect of biologics. Given the rapid pace of growth within the biopharmaceutical market, the demand for effective delivery systems is anticipated to increase in the foreseen future. This may be expected to create lucrative opportunities for stakeholders in the targeted drug delivery systems market.

Scope Of the Report

The ‘Organ-based/Targeted Drug Delivery Devices Market for Biologics (Intra-organ/Intra-tumoral), 2020-2030’ report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of such medical devices, over the next decade. The study features an in-depth analysis of the key drivers and trends related to this domain. Amongst other elements, the report includes:


  • A detailed assessment of the companies involved in the development of targeted delivery devices for biologics, providing information and analyses based on a number of relevant parameters, such as type of device (encapsulated device, catheter, implant, electroporation delivery system, balloon, cannula and microrobot), status of development (approved, clinical and preclinical), target organ (brain, heart, abdomen, breast, eye, and others), target indication (Parkinson's disease, heart failure, diabetes, breast cancer, myocardial infarction, Alzheimer’s, solid tumors (specific type unknown), and others), target therapeutic area (oncological disorders, neurological disorders, cardiovascular disorders, metabolic disorders and ophthalmic diseases), type of biologic delivered (cells, proteins, antibodies, enzymes, plasmids, growth factors, small peptides, neurotransmitters and modified RNA), type of therapy delivered (gene therapy, stem cell therapy, cell therapy, immunotherapy and RNA therapeutics) and route of administration (intra-tumoral, implantable, intraocular, intraputamen, intra-abdominal, intracardiac and others). In addition, the chapter includes information on the device developers, including details on type of stakeholder (industry and non-industry), year of establishment, company size (only for industry players) and location of headquarters.    
  • Elaborate profiles of devices that are currently approved or being evaluated in later stages of clinical development (phase III and above), featuring an overview of the device, its mechanism of action, current development status and key clinical trial results.
  • An assessment of the research activity in the neurological and cardiovascular disorders domain, in terms of the development of stem cell and gene therapies for the treatment these disorders. The chapter provides information and analysis on the recent publications and grants that are focused on the stem cell and gene therapies being developed for these therapeutic areas.
  • A clinical trial analysis of completed, ongoing and planned studies of various stem cell and gene therapies, based on various parameters, such as trial registration year, trial phase, trial status, type of sponsor/collaborator, type of therapy, therapeutic area, target indication, route of administration, key players, geographical location and enrolled patient population.
  • An analysis presenting the potential strategic partners (primarily stem cell and gene therapy developers) for targeted drug delivery device developers, based on different parameters, such as pipeline strength, target therapeutic area(s) and location of the headquarters of the company.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target patient population, likely adoption rates and expected pricing, we have provided an informed estimate of the likely evolution of the market, for the time period 2020-2030. Our year-wise projections for the current and future opportunity have further been segmented on the basis of [A] type of device (encapsulated device, catheter, electroporation delivery system, and cannula), [B] target organ (brain, heart, breast, eye, skin and pancreas), [C] target therapeutic area (oncological disorders, neurological disorders, cardiovascular disorders, metabolic disorders and ophthalmic diseases), [D] target indication (Parkinson's disease, heart failure, breast cancer, melanoma, glioblastoma, myocardial ischemia, geographic atrophy, glaucoma, macular telangectasia, retinitis pigmentosa, non-infectious uveitis and mucopolysaccharidosis type III A) and [E] key geographical regions (North America, Europe and Asia-Pacific). To account for the uncertainties associated with the development of the devices and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.  

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:


  • Dr William L Rust, Founder and Chief Executive Officer, Seraxis
  • Manuel Pires, Junior Business Developer, Defymed
  • R. Lyle Hood, Assistant Professor, University of Texas at San Antonio
  • Anonymous, Postdoctoral Associate, Massachusetts Institute of Technology  

All actual figures have been sourced and analysed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered


  • What type of devices are capable of providing targeted delivery of biologics?
  • Who are the leading device developers in this domain?
  • What are the key promising therapeutic areas for the development of targeted drug delivery devices for stem cell and gene therapies?
  • Which companies can be considered as potential strategic partners for device developers?
  • How is the current and future opportunity likely to be distributed across key market segments and geographical regions?

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4 Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Drug Delivery Devices for Biologics
3.3. Routes of Drug Administration
3.4. Challenges Associated with Drug Delivery
3.5. Need for Targeted Drug Delivery
3.6. Devices for Targeted Delivery of Biologics
3.6.1. Types of Devices
3.6.2. Key Advantages
3.7. Concluding Remarks
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Targeted Drug Delivery Devices for Biologics: Overall Market Landscape
4.2.1. Analysis by Type of Device
4.2.2. Analysis by Status of Development
4.2.3. Analysis by Target Organ
4.2.4. Analysis by Target Indication
4.2.5. Analysis by Target Therapeutic Area
4.2.6. Analysis by Type of Biologic Delivered
4.2.7. Analysis by Type of Therapy Delivered
4.2.8. Analysis by Route of Administration
4.3. Targeted Drug Delivery Devices for Biologics: Additional Information
4.4. Targeted Drug Delivery Devices for Biologics: List of Developers
4.4.1. Analysis by Type of Stakeholder
4.4.2. Analysis by Year of Establishment
4.4.3. Analysis by Company Size
4.4.4. Analysis by Location of Headquarters
5. DEVICE PROFILES
5.1. Chapter Overview
5.2. Alcyone MEMS Cannula (AMCTM)
5.2.1. Device Overview
5.2.2. Development Status
5.2.3. Key Clinical Trial Results
5.3. Bullfrog® Micro-Infusion Device
5.3.1. Device Overview
5.3.2. Development Status
5.3.3. Key Clinical Trial Results
5.4. HelixTM Biotherapeutic Delivery System
5.4.1. Device Overview
5.4.2. Development Status
5.4.3. Key Clinical Trial Results
5.5. Orbit Subretinal Delivery System
5.5.1. Device Overview
5.5.2. Development Status
5.5.3. Key Clinical Trial Results
5.6. SmartFlow® Neuro Ventricular Cannula
5.6.1. Device Overview
5.6.2. Development Status
5.6.3. Key Clinical Trial Results
5.7. Renexus®
5.7.1. Device Overview
5.7.2. Development Status
5.7.3. Key Clinical Trial Results
6. PROMISING THERAPEUTIC AREAS
6.1. Chapter Overview
6.2. Neurological Disorders
6.2.1. Stem Cell Therapies
6.2.1.1. Publication Analysis
6.2.1.1.1. Methodology
6.2.1.1.2. List of Publications
6.2.1.1.3. Analysis by Number of Publications
6.2.1.2. Grant Analysis
6.2.1.2.1. Methodology
6.2.1.2.2. List of Academic Grants
6.2.1.2.3. Analysis by Number of Grants
6.2.1.2.4. Analysis by Grant Amount
6.2.2. Gene Therapies
6.2.2.1. Publication Analysis
6.2.2.1.1. Methodology
6.2.2.1.2. List of Publications
6.2.2.1.3. Analysis by Number of Publications
6.2.2.2. Grant Analysis
6.2.2.2.1. Methodology
6.2.2.2.2. List of Academic Grants
6.2.2.2.3. Analysis by Number of Grants
6.2.2.2.4. Analysis by Grant Amount
6.3. Cardiovascular Disorders
6.3.1. Stem Cell Therapies
6.3.1.1. Publication Analysis
6.3.1.1.1. Methodology
6.3.1.1.2. List of Publications
6.3.1.1.3. Analysis by Number of Publications
6.3.1.2. Grant Analysis
6.3.1.2.1. Methodology
6.3.1.2.2. List of Academic Grants
6.3.1.2.3. Analysis by Number of Grants
6.3.1.2.4. Analysis by Grant Amount
6.3.2. Gene Therapies
6.3.2.1. Publication Analysis
6.3.2.1.1. Methodology
6.3.2.1.2. List of Publications
6.3.2.1.3. Analysis by Number of Publications
6.3.2.2. Grant Analysis
6.3.2.2.1. Methodology
6.3.2.2.2. List of Academic Grants
6.3.2.2.3. Analysis by Number of Grants
6.3.2.2.4. Analysis by Grant Amount
6.3. Summary of R&D Activity
7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Stem Cell and Gene Therapies: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Phase
7.3.3. Analysis by Trial Status
7.3.4. Analysis by Type of Sponsor/Collaborator
7.3.5. Analysis by Type of Therapy
7.3.6. Analysis by Therapeutic Area
7.3.7. Analysis by Therapeutic Indication
7.3.8. Analysis by Route of Administration
7.3.9. Analysis by Trial Status and Trial Phase
7.3.10. Most Active Industry Players: Analysis by Number of Registered Stem Cell and Gene Therapy Clinical Trials
7.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Stem Cell and Gene Therapy Clinical Trials
7.3.12. Analysis by Geographical Location
7.3.13. Analysis by Geographical Location and Trial Phase
7.3.14. Analysis by Geographical Location and Trial Status
7.3.15. Analysis by Geographical Location and Therapeutic Area
7.3.16. Analysis by Patients Enrolled and Trial Registration Year
7.3.17. Analysis by Patients Enrolled and Trial Phase
7.3.18. Analysis by Patients Enrolled and Type of Therapy
7.3.19. Analysis by Patients Enrolled and Therapeutic Area
7.3.20. Analysis by Patients Enrolled, Trial Status and Geographical Location
7.4. Stem Cell Therapies: Clinical Trial Analysis
7.4.1. Analysis by Trial Registration Year
7.4.2. Analysis by Trial Phase
7.4.3. Analysis by Trial Status
7.4.4. Analysis by Type of Sponsor/Collaborator
7.4.5. Analysis by Therapeutic Area
7.4.6. Analysis by Therapeutic Indication
7.4.7. Analysis by Route of Administration
7.4.8. Analysis by Trial Status and Trial Phase
7.4.9. Analysis by Geographical Location
7.4.10. Analysis by Geographical Location and Trial Phase
7.4.11. Analysis by Geographical Location and Trial Status
7.4.12. Analysis by Geographical Location and Therapeutic Area
7.4.13. Analysis by Patients Enrolled and Trial Registration Year
7.4.14. Analysis by Patients Enrolled and Trial Phase
7.4.15. Analysis by Patients Enrolled and Therapeutic Area
7.4.16. Analysis by Patients Enrolled, Trial Status and Geographical Location
7.5. Gene Therapies: Clinical Trial Analysis
7.5.1. Analysis by Trial Registration Year
7.5.2. Analysis by Trial Phase
7.5.3. Analysis by Trial Status
7.5.4. Analysis by Type of Sponsor/Collaborator
7.5.5. Analysis by Therapeutic Area
7.5.6. Analysis by Therapeutic Indication
7.5.7. Analysis by Route of Administration
7.5.8. Analysis by Trial Status and Trial Phase
7.5.9. Analysis by Geographical Location
7.5.10. Analysis by Geographical Location and Trial Phase
7.5.11. Analysis by Geographical Location and Trial Status
7.5.12. Analysis by Geographical Location and Therapeutic Area
7.5.13. Analysis by Patients Enrolled and Trial Registration Year
7.5.14. Analysis by Patients Enrolled and Trial Phase
7.5.15. Analysis by Patients Enrolled and Therapeutic Area
7.5.16. Analysis by Patients Enrolled, Trial Status and Geographical Location
8. LIKELY PARTNER ANALYSIS
8.1. Chapter Overview
8.2. Methodology and Key Parameters
8.3. Stem Cell Therapy Developers: Likely Partners for Device Developers
8.3.1. Opportunities in North America
8.3.1.1. Most Likely Partners
8.3.1.2. Likely Partners
8.3.1.3. Less Likely Partners
8.3.2. Opportunities in Europe
8.3.2.1. Most Likely Partners
8.3.2.2. Likely Partners
8.3.2.3. Less Likely Partners
8.3.3. Opportunities in Asia-Pacific and Rest of the World
8.3.3.1. Most Likely Partners
8.3.3.2. Likely Partners
8.3.3.3. Less Likely Partners
8.4. Gene Therapy Developers: Likely Partner for Device Developers
8.4.1. Opportunities in North America
8.4.1.1. Most Likely Partners
8.4.1.2. Likely Partners
8.4.1.3. Less Likely Partners
8.4.2. Opportunities in Europe
8.4.2.1. Most Likely Partners
8.4.2.2. Likely Partners
8.4.2.3. Less Likely Partners
8.4.3. Opportunities in Asia-Pacific and Rest of the World
8.4.3.1. Most Likely Partners
8.4.3.2. Likely Partners
8.4.3.3. Less Likely Partners
9. MARKET FORECAST
9.1. Chapter Overview
9.2. Forecast Methodology and Assumptions
9.3. Targeted Drug Delivery Devices Market for Biologics, 2022-2030
9.3.1. Targeted Drug Delivery Devices Market for Biologics: Distribution by Type of Device, 2022-2030
9.3.2. Targeted Drug Delivery Devices Market for Biologics: Distribution by Target Organ, 2022-2030
9.3.3. Targeted Drug Delivery Devices Market for Biologics: Distribution by Target Indication, 2022-2030
9.3.4. Targeted Drug Delivery Devices Market for Biologics: Distribution by Target Therapeutic Area, 2022-2030
9.3.5. Targeted Drug Delivery Devices Market for Biologics: Distribution by Key Geographical Regions, 2022-2030
9.3.5.1. Targeted Drug Delivery Devices Market for Biologics in North America, 2022-2030
9.3.5.2. Targeted Drug Delivery Devices Market for Biologics in Europe, 2022-2030
9.3.5.3. Targeted Drug Delivery Devices Market for Biologics in Asia-Pacific Region, 2022-2030
10. CONCLUDING REMARKS
10.1. Chapter Overview
10.2. Key Takeaways
11. EXECUTIVE INSIGHTS
11.1. Chapter Overview
11.2. Seraxis
11.2.1. Company Snapshot
11.2.2. Interview Transcript: Dr William L Rust, Founder and Chief Executive Officer
11.3. Defymed
11.3.1. Company Snapshot
11.3.2. Interview Transcript: Manuel Pires, Junior Business Developer
11.4. University of Texas at San Antonio
11.4.1. Organization Snapshot
11.4.2. Interview Transcript: R. Lyle Hood, Assistant Professor
11.5. Massachusetts Institute of Technology
11.5.1. Organization Snapshot
11.5.2. Interview Transcript: Anonymous, Postdoctoral Associate
12. APPENDIX 1: TABULATED DATA
List Of Figures
Figure 3.1 Drug Delivery Devices for Biologics
Figure 3.2 Routes of Drug Administration
Figure 4.1 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Device
Figure 4.2 Targeted Drug Delivery Devices for Biologics: Distribution by Status of Development
Figure 4.3 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Device and Status of Development
Figure 4.4 Targeted Drug Delivery Devices for Biologics: Distribution by Target Organ
Figure 4.5 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Device and Target Organ
Figure 4.6 Targeted Drug Delivery Devices for Biologics: Distribution by Target Indication
Figure 4.7 Targeted Drug Delivery Devices for Biologics: Distribution by Target Therapeutic Area
Figure 4.8 Targeted Drug Delivery Devices for Biologics: Distribution by Target Therapeutic Area and Status of Development
Figure 4.9 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Biologic Delivered
Figure 4.10 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Therapy Delivered
Figure 4.11 Targeted Drug Delivery Devices for Biologics: Distribution by Route of Administration
Figure 4.12 Targeted Drug Delivery Device Developers: Distribution by Type of Stakeholder
Figure 4.13 Targeted Drug Delivery Device Developers: Distribution by Year of Establishment
Figure 4.14 Targeted Drug Delivery Device Developers (Industry Players): Distribution by Company Size
Figure 4.15 Targeted Drug Delivery Device Developers (Industry Players): Distribution by Location of Headquarters
Figure 4.16 Targeted Drug Delivery Device Developers (Non-Industry Players): Distribution by Location of Headquarters
Figure 6.1 Stem Cell Therapies for Neurological Disorders, Publication Analysis: Cumulative Trend by Year, 2015-2020
Figure 6.2 Stem Cell Therapies for Neurological Disorders, Grants Analysis: Cumulative Year-wise Trend, 2015-2020
Figure 6.3 Stem Cell Therapies for Neurological Disorders, Grants Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Figure 6.4 Gene Therapies for Neurological Disorders, Publications Analysis: Cumulative Trend by Year, 2015-2020
Figure 6.5 Gene Therapies for Neurological Disorders, Grants Analysis: Cumulative Year-wise Trend, 2015-2020
Figure 6.6 Gene Therapies for Neurological Disorders, Grants Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Figure 6.7 Stem Cell Therapies for Cardiovascular Disorders, Publications Analysis: Cumulative Trend by Year, 2015-2020
Figure 6.8 Stem Cell Therapies for Cardiovascular Disorders, Grants Analysis: Cumulative Year-wise Trend, 2015-2020
Figure 6.9 Stem Cell Therapies for Cardiovascular Disorders, Grants Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Figure 6.10 Gene Therapies for Cardiovascular Disorders, Publications Analysis: Cumulative Trend by Year, 2015-2020
Figure 6.11 Gene Therapies for Cardiovascular Disorders, Grants Analysis: Cumulative Year-wise Trend, 2015-2020
Figure 6.12 Gene Therapies for Cardiovascular Disorders, Grants Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Figure 6.13 Summary of R&D Activity
Figure 7.1 Stem Cell and Gene Therapy Clinical Trials: Distribution by Trial Registration Year
Figure 7.2 Stem Cell and Gene Therapy Clinical Trials: Distribution by Trial Phase
Figure 7.3 Stem Cell and Gene Therapy Clinical Trials: Distribution by Trial Status
Figure 7.4 Stem Cell and Gene Therapy Clinical Trials: Distribution by Type of Sponsor/Collaborator
Figure 7.5 Stem Cell and Gene Therapy Clinical Trials: Distribution by Type of Therapy
Figure 7.6 Stem Cell and Gene Therapy Clinical Trials: Distribution by Therapeutic Area
Figure 7.7 Stem Cell and Gene Therapy Clinical Trials: Distribution by Therapeutic Indication
Figure 7.8 Stem Cell and Gene Therapy Clinical Trials: Distribution by Route of Administration
Figure 7.9 Stem Cell and Gene Therapy Clinical Trials: Distribution by Trial Status and Trial Phase
Figure 7.10 Most Active Industry Players: Distribution by Number of Registered Stem Cell and Gene Therapy Clinical Trials
Figure 7.11 Stem Cell and Gene Therapy: Most Active Non-Industry Players by Number of Registered Stem Cell and Gene Therapy Clinical Trials
Figure 7.12 Stem Cell and Gene Therapy Clinical Trials: Distribution by Geographical Location
Figure 7.13 Stem Cell and Gene Therapy Clinical Trials: Distribution by Geographical Location and Trial Phase
Figure 7.14 Stem Cell and Gene Therapy Clinical Trials: Distribution by Geographical Location and Trial Status
Figure 7.15 Stem Cell and Gene Therapy Clinical Trials: Distribution by Geographical Location and Therapeutic Area
Figure 7.16 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Registration Year
Figure 7.17 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Phase
Figure 7.18 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Type of Therapy
Figure 7.19 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Therapeutic Area
Figure 7.20 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled, Trial Status and Geographical Location
Figure 7.21 Stem Cell Therapy Clinical Trials: Distribution by Trial Registration Year
Figure 7.22 Stem Cell Therapy Clinical Trials: Distribution by Trial Phase
Figure 7.23 Stem Cell Therapy Clinical Trials: Distribution by Trial Status
Figure 7.24 Stem Cell Therapy Clinical Trials: Distribution by Type of Sponsor/Collaborator
Figure 7.25 Stem Cell Therapy Clinical Trials: Distribution by Therapeutic Area
Figure 7.26 Stem Cell Therapy Clinical Trials: Distribution by Route of Administration
Figure 7.27 Stem Cell Therapy Clinical Trials: Distribution by Trial Status and Trial Phase
Figure 7.28 Stem Cell Therapy Clinical Trials: Distribution by Geographical Location
Figure 7.29 Stem Cell Therapy Clinical Trials: Distribution by Geographical Location and Trial Phase
Figure 7.30 Stem Cell Therapy Clinical Trials: Distribution by Geographical Location and Trial Status
Figure 7.31 Stem Cell Therapy Clinical Trials: Distribution by Geographical Location and Therapeutic Area
Figure 7.32 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Registration Year
Figure 7.33 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Phase
Figure 7.34 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled and Type of Therapy
Figure 7.35 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled and Therapeutic Area
Figure 7.36 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled, Trial Status and Geographical Location
Figure 7.37 Gene Therapy Clinical Trials: Distribution by Trial Registration Year
Figure 7.38 Gene Therapy Clinical Trials: Distribution by Trial Phase
Figure 7.39 Gene Therapy Clinical Trials: Distribution by Trial Status
Figure 7.40 Gene Therapy Clinical Trials: Distribution by Type of Sponsor/Collaborator
Figure 7.41 Gene Therapy Clinical Trials: Distribution by Therapeutic Area
Figure 7.42 Gene Therapy Clinical Trials: Distribution by Route of Administration
Figure 7.43 Gene Therapy Clinical Trials: Distribution by Trial Status and Trial Phase
Figure 7.44 Gene Therapy Clinical Trials: Distribution by Geographical Location
Figure 7.45 Gene Therapy Clinical Trials: Distribution by Geographical Location and Trial Phase
Figure 7.46 Gene Therapy Clinical Trials: Distribution by Geographical Location and Trial Status
Figure 7.47 Gene Therapy Clinical Trials: Distribution by Geographical Location and Therapeutic Area
Figure 7.48 Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Registration Year
Figure 7.49 Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Phase
Figure 7.50 Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Type of Therapy
Figure 7.51 Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Therapeutic Area
Figure 7.52 Gene Therapy Clinical Trials: Distribution by Patients Enrolled, Trial Status and Geographical Location
Figure 8.1 Likely Partner Analysis: Distribution of Stem Cell Therapy Developers by Geography
Figure 8.2 Likely Partner Analysis: Distribution of Gene Therapy Developers by Geography
Figure 9.1. Targeted Drug Delivery Devices Market for Biologics, 2022-2030 (USD Million)
Figure 9.2. Targeted Drug Delivery Devices Market for Biologics, 2022-2030: Distribution by Type of Device (USD Million)
Figure 9.3. Targeted Drug Delivery Devices Market for Biologics, 2022-2030: Distribution by Target Organ (USD Million)
Figure 9.4. Targeted Drug Delivery Devices Market for Biologics, 2022-2030: Distribution by Target Indication (USD Million)
Figure 9.5. Targeted Drug Delivery Devices Market for Biologics, 2022-2030: Distribution by Target Therapeutic Area (USD Million)
Figure 9.6. Targeted Drug Delivery Devices Market for Biologics, 2022-2030: Distribution by Key Geographical Regions (USD Million)
Figure 9.7. Targeted Drug Delivery Devices Market for Biologics in North America, 2022-2030 (USD Million)
Figure 9.8. Targeted Drug Delivery Devices Market for Biologics in Europe, 2022-2030 (USD Million)
Figure 9.9. Targeted Drug Delivery Devices Market for Biologics in Asia-Pacific, 2022-2030 (USD Million)
List Of Tables
Table 4.1 Targeted Drug Delivery Devices for Biologics: List of Approved/Under Development Devices
Table 4.2 Targeted Drug Delivery Devices for Biologics: Information on Type of Biologic Delivered, Type of Therapy Delivered and Route of Administration
Table 4.3 Targeted Drug Delivery Devices for Biologics: Additional Information
Table 4.4 Targeted Drug Delivery Devices for Biologics: List of Developers
Table 5.1 Targeted Drug Delivery Devices for Biologics: List of Devices Profiled
Table 5.2 Alcyone MEMS Cannula (AMCTM): List/Details of Clinical Trials
Table 5.3 Bullfrog® Micro-Infusion Device: List/Details of Clinical Trials
Table 5.4 HelixTM Biotherapeutic Delivery System: List/Details of Clinical Trials
Table 5.5 Orbit Subretinal Delivery System: List/Details of Clinical Trials
Table 5.6 SmartFlow® Neuro Ventricular Cannula: List/Details of Clinical Trials
Table 5.7 Renexus®: List/Details of Clinical Trials
Table 6.1 Stem Cell Therapies for Neurological Disorders: List of Approved/Under Development Therapies
Table 6.2 Stem Cell Therapies for Neurological Disorders: List of Publications, 2015-2020
Table 6.3 Stem Cell Therapies for Neurological Disorders: List of Academic Grants, 2015-2020
Table 6.4 Gene Therapies for Neurological Disorders: List of Approved/Under Development Therapies
Table 6.5 Gene Therapies for Neurological Disorders: List of Publications, 2015-2020
Table 6.6 Gene Therapies for Neurological Disorders: List of Academic Grants, 2015-2020
Table 6.7 Stem Cell Therapies for Cardiovascular Disorders: List of Approved/Under Development Therapies
Table 6.8 Stem Cell Therapies for Cardiovascular Disorders: List of Publications, 2015-2020
Table 6.9 Stem Cell Therapies for Cardiovascular Disorders: List of Academic Grants, 2015-2020
Table 6.10 Gene Therapies for Cardiovascular Disorders: List of Approved/Under Development Therapies
Table 6.11 Gene Therapies for Cardiovascular Disorders: List of Publications, 2015-2020
Table 6.12 Gene Therapies for Cardiovascular Disorders: List of Academic Grants, 2015-2020
Table 8.1 Opportunities in North America: Most Likely Stem Cell Therapy Partners for Device Developers
Table 8.2 Opportunities in North America: Likely Stem Cell Therapy Partners for Device Developers
Table 8.3 Opportunities in North America: Less Likely Stem Cell Therapy Partners for Device Developers
Table 8.4 Opportunities in Europe: Most Likely Stem Cell Therapy Partners for Device Developers
Table 8.5 Opportunities in Europe: Likely Stem Cell Therapy Partners for Device Developers
Table 8.6 Opportunities in Europe: Less Likely Stem Cell Therapy Partners for Device Developers
Table 8.7 Opportunities in Asia-Pacific and Rest of the World: Most Likely Stem Cell Therapy Partners for Device Developers
Table 8.8 Opportunities in Asia-Pacific and Rest of the World: Likely Stem Cell Therapy Partners for Device Developers
Table 8.9 Opportunities in Asia-Pacific and Rest of the World: Less Likely Stem Cell Therapy Partners for Device Developers
Table 8.10 Opportunities in North America: Most Likely Gene Therapy Partners for Device Developers
Table 8.11 Opportunities in North America: Likely Gene Therapy Partners for Device Developers
Table 8.12 Opportunities in North America: Less Likely Gene Therapy Partners for Device Developers
Table 8.13 Opportunities in Europe: Most Likely Gene Therapy Partners for Device Developers
Table 8.14 Opportunities in Europe: Likely Gene Therapy Partners for Device Developers
Table 8.15 Opportunities in Europe: Less Likely Gene Therapy Partners for Device Developers
Table 8.16 Opportunities in Asia-Pacific and Rest of the World: Most Likely Gene Therapy Partners for Device Developers
Table 8.17 Opportunities in Asia-Pacific and Rest of the World: Likely Gene Therapy Partners for Device Developers
Table 8.18 Opportunities in Asia-Pacific and Rest of the World: Less Likely Gene Therapy Partners for Device Developers
Table 10.1 Targeted Drug Delivery Devices Market for Biologics: Key Takeaways
Table 11.1 Seraxis: Key Highlights
Table 11.2 Defymed: Key Highlights
Table 11.3 University of Texas at San Antonio: Key Highlights
Table 11.4 Massachusetts Institute of Technology: Key Highlights
Table 12.1 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Device
Table 12.2 Targeted Drug Delivery Devices for Biologics: Distribution by Status of Development
Table 12.3 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Device and Status of Development
Table 12.4 Targeted Drug Delivery Devices for Biologics: Distribution by Target Organ
Table 12.5 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Device and Target Organ
Table 12.6 Targeted Drug Delivery Devices for Biologics: Distribution by Target Indication
Table 12.7 Targeted Drug Delivery Devices for Biologics: Distribution by Target Therapeutic Area
Table 12.8 Targeted Drug Delivery Devices for Biologics: Distribution by Target Therapeutic Area and Status of Development
Table 12.9 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Biologic Delivered
Table 12.10 Targeted Drug Delivery Devices for Biologics: Distribution by Type of Therapy Delivered
Table 12.11 Targeted Drug Delivery Devices for Biologics: Distribution by Route of Administration
Table 12.12 Targeted Drug Delivery Device Developers: Distribution by Type of Stakeholder
Table 12.13 Targeted Drug Delivery Device Developers: Distribution by Year of Establishment
Table 12.14 Targeted Drug Delivery Device Developers (Industry Players): Distribution by Company Size
Table 12.15 Targeted Drug Delivery Device Developers (Industry Players): Distribution by Location of Headquarters
Table 12.16 Targeted Drug Delivery Device Developers (Non-Industry Players): Distribution by Location of Headquarters
Table 12.17 Stem Cell Therapies for Neurological Disorders, Publication Analysis: Cumulative Trend by Year, 2015-2020
Table 12.18 Stem Cell Therapies for Neurological Disorders, Grants Analysis: Cumulative Year-wise Trend, 2015-2020
Table 12.19 Stem Cell Therapies for Neurological Disorders, Grants Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Table 12.20 Gene Therapies for Neurological Disorders, Publications Analysis: Cumulative Trend by Year, 2015-2020
Table 12.21 Gene Therapies for Neurological Disorders, Grants Analysis: Cumulative Year-wise Trend, 2015-2020
Table 12.22 Gene Therapies for Neurological Disorders, Grants Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Table 12.23 Stem Cell Therapies for Cardiovascular Disorders, Publications Analysis: Cumulative Trend by Year, 2015-2020
Table 12.24 Stem Cell Therapies for Cardiovascular Disorders, Grants Analysis: Cumulative Year-wise Trend, 2015-2020
Table 12.25 Stem Cell Therapies for Cardiovascular Disorders, Grants Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Table 12.26 Gene Therapies for Cardiovascular Disorders, Publications Analysis: Cumulative Trend by Year, 2015-2020
Table 12.27 Gene Therapies for Cardiovascular Disorders, Grants Analysis: Cumulative Year-wise Trend, 2015-2020
Table 12.28 Gene Therapies for Cardiovascular Disorders, Grants Analysis: Cumulative Year-Wise Distribution by Grant Amount (USD Million)
Table 12.29 Stem Cell and Gene Therapy Clinical Trials: Distribution by Trial Registration Year
Table 12.30 Stem Cell and Gene Therapy Clinical Trials: Distribution by Trial Phase
Table 12.31 Stem Cell and Gene Therapy Clinical Trials: Distribution by Trial Status
Table 12.32 Stem Cell and Gene Therapy Clinical Trials: Distribution by Type of Sponsor/Collaborator
Table 12.33 Stem Cell and Gene Therapy Clinical Trials: Distribution by Type of Therapy
Table 12.34 Stem Cell and Gene Therapy Clinical Trials: Distribution by Therapeutic Area
Table 12.35 Stem Cell and Gene Therapy Clinical Trials: Distribution by Therapeutic Indication
Table 12.36 Stem Cell and Gene Therapy Clinical Trials: Distribution by Route of Administration
Table 12.37 Stem Cell and Gene Therapy Clinical Trials: Distribution by Trial Status and Trial Phase
Table 12.38 Most Active Industry Players: Distribution by Number of Registered Stem Cell and Gene Therapy Clinical Trials
Table 12.39 Stem Cell and Gene Therapy: Most Active Non-Industry Players by Number of Registered Stem Cell and Gene Therapy Clinical Trials
Table 12.40 Stem Cell and Gene Therapy Clinical Trials: Distribution by Geographical Location
Table 12.41 Stem Cell and Gene Therapy Clinical Trials: Distribution by Geographical Location and Trial Phase
Table 12.42 Stem Cell and Gene Therapy Clinical Trials: Distribution by Geographical Location and Trial Status
Table 12.43 Stem Cell and Gene Therapy Clinical Trials: Distribution by Geographical Location and Therapeutic Area
Table 12.44 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Registration Year
Table 12.45 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Phase
Table 12.46 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Type of Therapy
Table 12.47 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Therapeutic Area
Table 12.48 Stem Cell and Gene Therapy Clinical Trials: Distribution by Patients Enrolled, Trial Status and Geographical Location
Table 12.49 Stem Cell Therapy Clinical Trials: Distribution by Trial Registration Year
Table 12.50 Stem Cell Therapy Clinical Trials: Distribution by Trial Phase
Table 12.51 Stem Cell Therapy Clinical Trials: Distribution by Trial Status
Table 12.52 Stem Cell Therapy Clinical Trials: Distribution by Type of Sponsor/Collaborator
Table 12.53 Stem Cell Therapy Clinical Trials: Distribution by Therapeutic Area
Table 12.54 Stem Cell Therapy Clinical Trials: Distribution by Route of Administration
Table 12.55 Stem Cell Therapy Clinical Trials: Distribution by Trial Status and Trial Phase
Table 12.56 Stem Cell Therapy Clinical Trials: Distribution by Geographical Location
Table 12.57 Stem Cell Therapy Clinical Trials: Distribution by Geographical Location and Trial Phase
Table 12.58 Stem Cell Therapy Clinical Trials: Distribution by Geographical Location and Trial Status
Table 12.59 Stem Cell Therapy Clinical Trials: Distribution by Geographical Location and Therapeutic Area
Table 12.60 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Registration Year
Table 12.61 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Phase
Table 12.62 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled and Type of Therapy
Table 12.63 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled and Therapeutic Area
Table 12.64 Stem Cell Therapy Clinical Trials: Distribution by Patients Enrolled, Trial Status and Geographical Location
Table 12.65 Gene Therapy Clinical Trials: Distribution by Trial Registration Year
Table 12.66 Gene Therapy Clinical Trials: Distribution by Trial Phase
Table 12.67 Gene Therapy Clinical Trials: Distribution by Trial Status
Table 12.68 Gene Therapy Clinical Trials: Distribution by Type of Sponsor/Collaborator
Table 12.69 Gene Therapy Clinical Trials: Distribution by Therapeutic Area
Table 12.70 Gene Therapy Clinical Trials: Distribution by Route of Administration
Table 12.71 Gene Therapy Clinical Trials: Distribution by Trial Status and Trial Phase
Table 12.72 Gene Therapy Clinical Trials: Distribution by Geographical Location
Table 12.73 Gene Therapy Clinical Trials: Distribution by Geographical Location and Trial Phase
Table 12.74 Gene Therapy Clinical Trials: Distribution by Geographical Location and Trial Status
Table 12.75 Gene Therapy Clinical Trials: Distribution by Geographical Location and Therapeutic Area
Table 12.76 Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Registration Year
Table 12.77 Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Trial Phase
Table 12.78 Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Type of Therapy
Table 12.79 Gene Therapy Clinical Trials: Distribution by Patients Enrolled and Therapeutic Area
Table 12.80 Gene Therapy Clinical Trials: Distribution by Patients Enrolled, Trial Status and Geographical Location
Table 12.81 Likely Partner Analysis: Distribution of Stem Cell Therapy Developers by Geography
Table 12.82 Likely Partner Analysis: Distribution of Gene Therapy Developers by Geography
Table 12.83 Targeted Drug Delivery Devices Market for Biologics, Conservative, Base and Optimistic Scenarios, 2022-2030 (USD Million)
Table 12.84 Targeted Drug Delivery Devices Market for Biologics, Conservative, Base and Optimistic Scenarios, 2022-2030: Distribution by Type of Device (USD Million)
Table 12.85 Targeted Drug Delivery Devices Market for Biologics, Conservative, Base and Optimistic Scenarios, 2022-2030: Distribution by Target Organ (USD Million)
Table 12.86 Targeted Drug Delivery Devices Market for Biologics, Conservative, Base and Optimistic Scenarios, 2022-2030: Distribution by Target Indication (USD Million)
Table 12.87 Targeted Drug Delivery Devices Market for Biologics, Conservative, Base and Optimistic Scenarios, 2022-2030: Distribution by Target Therapeutic Area (USD Million)
Table 12.88 Targeted Drug Delivery Devices Market for Biologics, Conservative, Base and Optimistic Scenarios, 2022-2030: Distribution by Key Geographical Regions (USD Million)
Table 12.89 Targeted Drug Delivery Devices Market for Biologics in North America, Conservative, Base and Optimistic Scenarios, 2022-2030 (USD Million)
Table 12.90 Targeted Drug Delivery Devices Market for Biologics in Europe, Conservative, Base and Optimistic Scenarios, 2022-2030 (USD Million)
Table 12.91 Targeted Drug Delivery Devices Market for Biologics in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2022-2030 (USD Million)

Companies Mentioned

  • 4D Molecular Therapeutics
  • AbbVie
  • Abeona Therapeutics
  • Advanced Materials and BioEngineering Research
  • Advantagene
  • Advaxis
  • Adverum Biotechnologies
  • Alcyone Lifesciences
  • Allergan
  • AlphaVax
  • Altaco XXI
  • American Gene Technologies International
  • Amgen
  • Amicus Therapeutics
  • Anaeropharma Science
  • Anchiano Therapeutics
  • AnGes
  • Angionetics
  • apceth Biopharma
  • Apic Bio
  • Applied Genetic Technologies Corporation
  • AskBio
  • Astellas Pharma
  • Athersys
  • Atrium Medical
  • Austrianova
  • AveXis
  • Axis Biotec Brasil
  • Axovant
  • Azidus Brasil
  • BHI Therapeutic Sciences
  • BioCardia
  • Biogen
  • BioGenCell
  • BioInvent
  • Bioquark
  • BioRestorative Therapies
  • Biosense Webster
  • bluebird bio
  • Boehringer Ingelheim
  • Bone Therapeutics
  • Boston Scientific
  • Boston TransTec
  • BrainStorm Cell Therapeutics
  • Bristol-Myers Squibb
  • Bukwang Pharmaceutical
  • Caladrius Biosciences
  • California Institute for Regenerative Medicine
  • Capricor Therapeutics
  • CAR-T (Shanghai) Biotechnology
  • Celixir
  • CellProthera
  • Celsion
  • Celyad
  • Cesca Therapeutics
  • CHA Biotech
  • Children's Hospital of Chongqing Medical University
  • Chonbuk National University
  • ClearPoint Neuro
  • Cold Genesys
  • CombiGene
  • Cook Regentec
  • Copernicus Therapeutics
  • Corestem
  • Cornell University
  • CRISPR Therapeutics
  • Cynvec
  • Cytopeutics
  • Daegu Gyeongbuk Institute of Science & Technology
  • Defymed
  • DiscGenics
  • DNAlite Therapeutics
  • DNAtrix
  • Duke University
  • EdiGene
  • Editas Medicine
  • Endsulin
  • Epeius Biotechnologies
  • Ever Supreme Bio Technology
  • Eyevensys
  • Ferrer Internacional
  • FKD Therapies
  • Gemini Therapeutics
  • Genelux
  • Genenta Science
  • Genentech
  • Generation Bio
  • Genexine
  • Genprex
  • GenSight Biologics
  • Global Cell Med
  • Gloriana Therapeutics
  • Gradalis
  • Gwo Xi Stem Cell
  • Gyroscope Therapeutics
  • Harvard University
  • Hebei Newtherapy BIo-Pharma Technology
  • Hemera Biosciences
  • Hemostemix
  • Hitachi Chemical
  • Homology Medicines
  • Hope Biosciences
  • HORAMA
  • Houston Methodist Research Institute
  • Inovio Pharmaceuticals
  • Institute of Robotic and Intelligent Systems
  • IVERIC bio
  • Janssen
  • Japan Regenerative Medicine
  • Japan Tissue Engineering
  • jCyte
  • Jennerex Biotherapeutics
  • Juventas Therapeutics
  • Kadimastem
  • Karolinska Institutet
  • Kolon TissueGene
  • K-Stem Cell
  • Kubota Pharmaceutical
  • Lacerta Therapeutics
  • Lifecells
  • Lineage Cell Therapeutics
  • Living Cell Technologies
  • Lokon Pharma
  • Longeveron
  • Lysogene
  • Marsala Biotech
  • Massachusetts Institute of Technology
  • Med Cell Bahamas
  • MedImmune
  • MEDIPOST
  • MeiraGTx
  • Mercator MedSystems
  • Merck
  • Meridigen Biotech
  • Mesoblast
  • Michael J. Fox Foundation
  • Momotaro-Gene
  • MultiVir
  • NanoCor Therapeutics
  • National Cancer Institute
  • National University of Ireland, Galway
  • Nature Cell
  • Neuracle Genetics
  • Neuralgene
  • Neurocrine Biosciences
  • Neurogene
  • NeuroGeneration
  • Neurotech Pharmaceuticals
  • NextCell Pharma
  • Nightstar Therapeutics
  • Nipro
  • Noray Biosciences Group
  • Novadip Biosciences
  • Novartis
  • Novo Nordisk
  • NuVasive
  • Ocugen
  • Oncolys BioPharma
  • Oncos Therapeutics
  • OncoSec Medical
  • Orbit Biomedical
  • ORCA Therapeutics
  • Oxford BioMedica
  • Passage Bio
  • Pattern BioScience
  • PeriphaGen
  • Pfizer
  • PharmaCyte Biotech
  • Pharmicell
  • Pluristem Therapeutics
  • Plus Therapeutics
  • Prevail Therapeutics
  • Promethera Biosciences
  • PsiOxus Therapeutics
  • PTC Therapeutics
  • Q Therapeutics
  • Regeneron Pharmaceuticals
  • REGENXBIO
  • Reliance Life Sciences
  • ReNeuron
  • Renishaw
  • Renova Therapeutics
  • Riordan Technologies
  • Roche
  • ROHTO Pharmaceutical
  • Royal College of Surgeons in Ireland
  • SanBio
  • Sangamo Therapeutics
  • Sanofi
  • Sarepta Therapeutics
  • Scancell
  • Sclnow Biotechnology
  • SCM LifeScience
  • Seneca Biopharma
  • Sentien Biotechnologies
  • Seraxis
  • Shandong Qilu Stem Cells Engineering
  • Shanghai East Hospital
  • Shanghai Sunway Biotech
  • Shenzhen Hornetcorn Biotechnology
  • Shire
  • Sibiono GeneTech
  • Sigilon Therapeutics
  • SillaJen
  • Smartwise
  • SOTIO
  • Southwest Research Institute
  • Spark Therapeutics
  • Stem Med
  • Stemedica Cell Technologies
  • Steminent Biotherapeutics
  • Stempeutics Research
  • StrideBio
  • SWIB Holding
  • Taiwan Bio Therapeutics
  • Takeda
  • Targovax
  • Taxus Cardium Pharmaceuticals
  • Tenaya Therapeutics
  • The Emmes Company
  • TheraBiologics
  • Theravectys
  • Tianhe Stem Cell Biotechnologies
  • Tianjin Weikai Biological Engineering
  • TICEBA
  • Tocagen
  • Transgene
  • Translational Research Institute
  • TransVascular
  • Trinity College Dublin
  • U.S. Stem Cell
  • Ultragenyx Pharmaceutical
  • uniQure
  • United Therapeutics
  • University of Milan
  • University of Minnesota Medical School
  • University of Pennsylvania
  • University of Texas
  • VBL Therapeutics
  • VcanBio Center for Translational Biotechnology
  • VCN Biosciences
  • Vericel
  • Verve Therapeutics
  • Vessl
  • ViroMed
  • Virttu Biologics
  • Viscofan BioEngineering
  • Voyager Therapeutics
  • XyloCor Therapeutics

Methodology

 

 

Loading
LOADING...

Related Topics

Related Reports

Global Biologics Contract Manufacturing (Biopharma CDMO/Biopharma CMO/Biologics Manufacturing) Market 2022-2035 by Type of Service(s) Offered, Type of Biologic Manufactured, Type of Expression System Used, Scale of Operation, Company Size, and Key Geographical Regions - Product Image

Global Biologics Contract Manufacturing (Biopharma CDMO/Biopharma CMO/Biologics Manufacturing) Market 2022-2035 by Type of Service(s) Offered, Type of Biologic Manufactured, Type of Expression System Used, Scale of Operation, Company Size, and Key Geographical Regions

  • Report
  • 799 Pages
  • Global
From
Cancer Biologics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Image

Cancer Biologics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • 178 Pages
  • Global
From
Cell & Gene Therapy Drug Delivery Devices Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type, By Commercialized Drugs, By Route of Administration, By Method, By Region and Competition - Product Image

Cell & Gene Therapy Drug Delivery Devices Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type, By Commercialized Drugs, By Route of Administration, By Method, By Region and Competition

  • Report
  • 110 Pages
  • Global
From
Single Use Bioreactors Market (3rd Edition) - Distribution by Type of Bioreactor, Scale of Operation, Type of Cell Culture, Type of Biologics Synthesized, Application Area, End-users, and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035 - Product Image

Single Use Bioreactors Market (3rd Edition) - Distribution by Type of Bioreactor, Scale of Operation, Type of Cell Culture, Type of Biologics Synthesized, Application Area, End-users, and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035

  • Report
  • 356 Pages
  • Global
From
Biologics Market Report by Source, Product, Disease, Manufacturing, and Region 2024-2032 - Product Image

Biologics Market Report by Source, Product, Disease, Manufacturing, and Region 2024-2032

  • Report
  • 138 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.